Search is Powered by Google
Pain / Anesthetics News

Idiopathic Pain Disorders Pathways Of Vulnerability

Main Category: Pain / Anesthetics
Also Included In: Psychology / Psychiatry
Article Date: 21 Nov 2007 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article


Current Article Ratings:

Patient / Public:4 and a half stars

4.29 (7 votes)

Health Professional:not yet rated

Article Opinions: 2 posts

UroToday.com- Idiopathic pain disorders (IPDs) consist of such conditions as temporomndibular joint disorders, fibromyalgia syndrome, irritable bowel syndrome, chronic headaches, interstitial cystitis, chronic pelvic pain, chronic tinnitus, whiplash-associated disorders, and vulvar vestibulitis. IPSs commonly aggregate as "comorbid" conditions that are characterized by a complaint of pain as well as a mosaic of abnormalities in motor function, autonomic balance, neuroendocrine function, and sleep. In a very interesting article Diatchenko and coworkers from North Carolina, Florida, and Adelaide Australia review IPSs and proposed pathways of vulnerability that link these disorders

IPDs have been associated with a state of pain amplification and psychological distress. There is substantial individual variability in the relative contribution of pain amplification and psychological phenotypes to IPDs. The authors suggest that pain amplification and psychological distress, which are mediated by an individual's genetic variability and exposure to environmental events, represent two primary pathways of vulnerability that underlie the development of highly prevalent IPDs.

A well-established predictor of onset is the presence of another chronic pain condition, characterized by a state of pain amplification. For temporo-mandibular joint (TMJ) disorders not only is widespread pain a risk indicator for TMJ, but also for a lack of response to treatment. The condition is more likely to develop in those individuals more sensitive to noxious stimuli. A relatively high percentage of patients with IPDs show enhanced responses to noxious stimulation compared to controls. The enhanced pain perception may result from a disregulation in peripheral afferent and central nervous system pathways that produce dynamic, time-dependent changes in the excitability, and response characteristics of neuronal and glial cells.

This review advances the notion that we should look for similarities in chronic pain syndromes that may yield keys to treatment of this group of disorders. Because it is highly likely that IPDs share common underlying pathophysiological mechanisms it is expected that the same functional genetic variants will often be associated with comorbid IPDs and related signs and symptoms.

Diatchenko L, Nackley AG, Slade GD, Fillingim RB and Maixner W

Pain. 123(3):226-230, July 2006
doi:10.1016/j.pain.2006.04.015

Reported by UroToday.com Contributing Editor Philip M. Hanno, M.D

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday.com

----------------------------
Copyright © 2007 - UroToday
Reproduced for Medical News Today with permission of UroToday.
----------------------------




Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
FDA Approves Fibromyalgia Drug - Savella(TM) (milnacipran HCl), A Selective Serotonin And Norepinephrine Dual Reuptake Inhibitor
16 Jan 2009
Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB) today announced that Savella(TM) (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor, was approved by the U.S...


Treating Chronic Pain image Treating Chronic Pain

Chronic pain is pain that continues past the normal healing time for an injury. Learn about the causes and current treatment options, from NSAIDs to opioids, for chronic pain...

What Is Chronic Pain? image What Is Chronic Pain?

Chronic pain can affect a person 24 hours a day. What causes chronic pain? And how can you get some relief...

View more videos...